LeMaitre Vascular, Inc. (LMAT) News

LeMaitre Vascular, Inc. (LMAT): $45.13

0.33 (+0.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter LMAT News Items

LMAT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LMAT News Highlights

  • LMAT's 30 day story count now stands at 10.
  • Over the past 24 days, the trend for LMAT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • BEAT, DAVE and NUVA are the most mentioned tickers in articles about LMAT.

Latest LMAT News From Around the Web

Below are the latest news stories about Lemaitre Vascular Inc that investors may wish to consider to help them evaluate LMAT as an investment opportunity.

LeMaitre Vascular's (LMAT) CEO George LeMaitre on Q4 2021 Results - Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants JJ Pellegrino – Chief Financial Officer George LeMaitre – Chairman and Chief Executive Officer Dave Roberts – President Conference Call Participants Brooks O’Neil – Lake Street Scott Henry – Roth Capital Zachary Weiner...

SA Transcripts on Seeking Alpha | February 25, 2022

LeMaitre Vascular (LMAT) Misses Q4 Earnings and Revenue Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of -9.68% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

LeMaitre Q4 2021 Financial Results

BURLINGTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2021 results, announced a $0.125/share quarterly dividend (+14%) and provided guidance. Q4 2021 Financial Results Sales of $39.5mm, +5% (+6% organic) vs. Q4 2020Op. income of $8.3mm, -13%Op. margin of 21%Net income of $6.2mm, -12%Earnings of $0.28 per diluted share, -18%Cash and investments +$2.9mm to $70.0mm Q4 2021 sales were driven by bovine gra

Yahoo | February 24, 2022

NuVasive (NUVA) Q4 Earnings Lag Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -14.89% and 1.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

LeMaitre Will Announce Fourth Quarter 2021 Earnings Results February 24, 2022

BURLINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

GlobeNewswire | February 11, 2022

LeMaitre to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

BURLINGTON, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 16, 2022, at 10:30 AM ET. LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures

Yahoo | February 9, 2022

Knowledge Leaders Capital, LLC Buys MaxLinear Inc, Broadcom Inc, Omnicell Inc, Sells Schwab U.S. ...

Investment company Knowledge Leaders Capital, LLC (Current Portfolio) buys MaxLinear Inc, Broadcom Inc, Omnicell Inc, Amphenol Corp, NetApp Inc, sells Schwab U.S.

Yahoo | February 2, 2022

Could The Market Be Wrong About LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Its Attractive Financial Prospects?

With its stock down 20% over the past three months, it is easy to disregard LeMaitre Vascular (NASDAQ:LMAT). However...

Yahoo | February 1, 2022

AHCO vs. LMAT: Which Stock Should Value Investors Buy Now?

AHCO vs. LMAT: Which Stock Is the Better Value Option?

Yahoo | January 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.492 seconds.